Form 4 Roivant Sciences Ltd. For: May 23 Filed by: Gline Matthew
Roivant Sciences Ltd. (ROIV)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at JPMorgan Chase & Co. from $12.00 to $14.00.MarketBeat
- S&P 500 Futures Rise in Premarket Trading; Roivant Sciences, Dynatrace Lead [Barron's]Barrons
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at HC Wainwright from $14.00 to $15.00.MarketBeat
- Roivant stock rises after Vtama meets main goal of 2nd phase 3 eczema study [Seeking Alpha]Seeking Alpha
- Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years OldGlobeNewswire
ROIV
Earnings
- 2/13/23 - Miss
ROIV
Sec Filings
- 5/25/23 - Form 4
- 5/25/23 - Form 4
- 5/25/23 - Form 144
- ROIV's page on the SEC website